Age at diagnosis, years Median (range) | 29.3 (14.6 – 63.6) |
Observation time, months Median (range) | 11.8 (4.3 – 19.3) |
Age at survey, years Median (range) | 42.3 (22.7 – 73.4) |
Histology, number (%) | Seminoma: 44 (18.5%) Non-seminoma: 194 (81.5%) |
Stage according to Royal Marsden Hospital, number of patients (%) | I: 72 (30.2%, incl. 2 IM) |
II: 101 (42.4%) | |
III: 13 (5.5%) | |
IV: 52 (21.8%) | |
Number of cycles of chemotherapy | 1–3: 52 (21.8%) 4: 141 (59.2%) 5–7: 34 (14.3%) >8: 11 (4.6%) |
First Regimen (n = 238) Completed by 100% of TCSs | BEP: 104 (43.7%), CVB: 104 (43.7%), BOPVIP: 10 (4.2%), Others: 20 (8.4%) |
Second Regimen (n = 44) Completed by 18.5% of TCSs | BEP: 17 (39%), VIP: 12 (27%), EP: 5 (11%), Others: 10 (23%) |
Third regimen (n = 8) | VIP: 2, EP: 2, Others: 4 |
Fourth Regimen (n = 1) | EP: 1 |
Number of TCSs exposed to the most common cytotoxic agents and cumulative doses among those [mg/m2], median (range) | Cisplatin (n = 238) : 397 (81 – 1571) Bleomycin (n = 226) : 145 (29–212) Vinblastine (n = 105) : 35 (10–51) Etoposide (n = 146) : 1434 (41–4934) |